BioLingus AG articles
We plan to develop sublingual interferon-alfa for the prevention of viral infections, such as influenza and coronaviruses (such as COVID-19).
The rise in prevalence of viral respiratory infections in humans and increase in health care expenditure are projected to boost the growth of the global respiratory antiviral treatment market. Respiratory syncytial virus, influenza virus, para
Semaglutide is currently the only GLP-1 product available as an oral product. Biolingus aims at developing a sublingual version of this product. This should have a substantially lower COGS and hence competitive with the oral version.
Liraglutide and exenatide are both belonging to the class of diabetes products called GLP-1 analogues. The GLP-1 analogues have established themselves in the past years as one of the superior drug classes for treatment of diabetes type II in terms of blood glucose lowering and weight loss. Because of the latter, they are being used more and more also in the treatment of obesity.
Until now, both drugs are only available by injection. With the BioLingus drug delivery technology, both
Biolingus explores the development of a sublingual dual incretin inhibitor.
BioLingus will position these products in the “epidemic” markets of obesity and type II diabetes :
- More than 400 MM people suffer from diabetes today. The global type 2 diabetes market is expected to grow to $58.7 billion by 2025, with an annual growth rate of 6.5%, according to research and consulting firm GlobalData.
- According to WHO, more than 1.9 billion adults, 18 year
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone.
Such a fixed dose combination is already on the market under the brand name Xultophy, which is a combination of insulin degludec and liraglutide injection.
Advantages of an insulin+ produc